Compare USAC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USAC | LQDA |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | N/A | 2018 |
| Metric | USAC | LQDA |
|---|---|---|
| Price | $25.07 | $30.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $25.00 | ★ $37.40 |
| AVG Volume (30 Days) | 256.5K | ★ 2.2M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | ★ 8.44% | N/A |
| EPS Growth | ★ 43.67 | N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $991,507,000.00 | $69,216,000.00 |
| Revenue This Year | $7.32 | $424.31 |
| Revenue Next Year | $4.51 | $359.32 |
| P/E Ratio | $30.77 | ★ N/A |
| Revenue Growth | 6.66 | ★ 343.41 |
| 52 Week Low | $21.53 | $10.37 |
| 52 Week High | $30.10 | $32.80 |
| Indicator | USAC | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 65.90 | 60.95 |
| Support Level | $23.40 | $27.76 |
| Resistance Level | $26.07 | $32.80 |
| Average True Range (ATR) | 0.72 | 1.78 |
| MACD | 0.19 | 0.20 |
| Stochastic Oscillator | 70.28 | 68.59 |
USA Compression Partners LP provides compression services in the United States in terms of total compression fleet horsepower to customers relating to infrastructure applications, including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. It engineers, designs, operates, services, and repairs its compression units and maintains related support inventory and equipment. The company provides compression services in several shale plays throughout the U.S., including the Utica, Marcellus, Permian, Denver-Julesburg, Eagle Ford, Mississippi Lime, Granite Wash, Woodford, Barnett, and Haynesville.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.